Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

In Silico Immunogenicity Screening, Xencor Inc.
February 2006
SHARING OPTIONS:

Xencor, Inc., a biotechnology company developing biotherapeutics to treat a variety of diseases, announced the launch of ImmunoFilter technology, a software product that can predict immunogenicity of therapeutic proteins and monoclonal antibodies early in the drug discovery pathway.  Immunogenicity of biotherapeutics can decrease efficacy and potency and has been difficult to predict with existing methods.  According to Xencor, currently nine out of ten experimental drugs fail in clinical studies and immunogenicity is the leading reason that biotherapeutics fail in clinical trials.  Immunogenicity can be seen in humanized protein therapeutics including insulin, which can evoke immune response in up to 44 percent of patients. The unpredictable nature of an immune response to a biotherapeutic has also raised awareness within the FDA, where the implementation of the "critical path to new medical products" focuses on the development of new tools to predict efficacy and safety early in the development process. Xencor's ImmunoFilter product is able to examine a protein sequence for "hot spots" that might cause an immune response.  ImmunoFilter consists of an experimentally determined database of peptide sequences that favor immune response initiation and software that integrates the database with the queried protein sequence to provide a score on the protein's ability to cause an immune response.  Xencor expects to be able to predict the potential immunogenicity in more than 95 percent of the U.S. population.
 
Xencor
626.305.5900

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.